DIA 2026 Global Annual Meeting
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to DIA 2026 Global Annual Meeting — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
DIA 2026 Global Annual Meeting
Event type: Life sciences, drug development, clinical research, regulatory affairs, healthcare innovation, pharma services, medical affairs, biotech partnering
Likely audience profile: A highly qualified B2B audience made up of pharma, biotech, clinical operations, regulatory, safety, medical affairs, R&D, quality, market access, digital health, CRO, and service-provider decision makers
Estimated attendance: Typically a large global industry gathering; for planning and list-building purposes, expect several thousand attendees with strong representation from North America, Europe, and other international pharma and biotech hubs
1️⃣ Who attends: Buyers / attendees
The DIA Global Annual Meeting is one of the strongest life sciences and drug development conferences for reaching commercial and operational decision makers. Unlike consumer healthcare events, this meeting is built around the ecosystem that supports pharmaceutical development, clinical trials, regulatory submission, drug safety, market access, and healthcare innovation.
The attendee base is typically made up of senior and mid-level professionals from pharmaceutical companies, biotechnology companies, contract research organizations, medical device firms, digital health companies, consulting firms, regulators, academics, hospitals, and technology vendors serving life sciences.
Main attendee groups include:
- Clinical operations leaders
- Clinical trial managers and project directors
- Regulatory affairs directors and managers
- Drug safety / pharmacovigilance professionals
- Medical affairs and medical science liaison leaders
- R&D and translational research leaders
- Biostatistics and data science teams
- Quality, compliance, and validation professionals
- Market access and HEOR professionals
- CRO executives and business development leaders
- Pharma IT, AI, digital transformation, and data management teams
- Patient engagement, real-world evidence, and decentralized trial stakeholders
- Consultants and solution providers serving the life sciences market
- Academics, researchers, and public health professionals
For attendee-list sales, the highest-value buyers are usually not students or general visitors; they are the professionals tied to budget ownership, vendor evaluation, outsourcing, compliance, and platform adoption.
2️⃣ Where the show is happening + attendee geographic origin
The exact host city for DIA 2026 Global Annual Meeting should be confirmed from the official event page, because this meeting rotates and the location can vary by year. For list strategy, what matters most is that this is a global life sciences event with a broad geographic footprint.
Attendee origin typically includes:
- United States and Canada
- Western and Central Europe
- United Kingdom and Ireland
- India
- Japan, South Korea, Singapore, and other APAC markets
- Middle East life sciences hubs
- Latin America and emerging biotech markets
Because DIA is a global association-focused meeting, the attendee mix is usually international and cross-functional. That makes it especially useful for buyers who sell across borders, offer multi-country clinical operations support, or need access to a global pharma network.
3️⃣ Audience reach: Local / National / Global
Audience reach: Global
This event is not limited to a local or national market. It is designed for international participation, and the most relevant companies attending are usually global pharmaceutical, biotech, CRO, medtech, and research organizations.
The event is especially valuable for vendors and service providers seeking:
- Global pharma accounts
- Multi-regional clinical trial buyers
- Regulatory and compliance teams
- Drug development and medical affairs leadership
- Innovation buyers across life sciences
4️⃣ Sample buyer company names + websites
Below are sample buyer accounts that are strong targets for attendee-list intelligence. These are selected because they typically have active investment in clinical development, regulatory operations, safety, digital transformation, or outsourced research services.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Pfizer | pfizer.com | Director, Clinical Operations | Global pharma buyer with active clinical, medical, and R&D functions that regularly evaluate external services and technologies. |
| 2 | Roche | roche.com | Head of Regulatory Affairs | Strong fit for regulatory, diagnostics, clinical, and digital health decision makers in a highly global organization. |
| 3 | Novartis | novartis.com | Global Program Manager, Clinical Development | Large international buyer with major budgets across development, medical affairs, and real-world evidence. |
| 4 | Johnson & Johnson | jnj.com | Director, Medical Affairs | Broad healthcare and life sciences footprint with strong interest in clinical evidence, patient support, and innovation partnerships. |
| 5 | Merck & Co. | merck.com | Director, Drug Safety / Pharmacovigilance | Excellent buyer for safety, compliance, clinical data, and post-market surveillance solutions. |
| 6 | GSK | gsk.com | VP, Clinical Operations | Global research-driven pharma company with major needs in trial execution, operations, and vendor management. |
| 7 | AstraZeneca | astrazeneca.com | Director, Clinical Data Management | Highly relevant for data, analytics, decentralized trial tools, and global study oversight. |
| 8 | Sanofi | sanofi.com | Head of Regulatory Strategy | Strong fit for global regulatory and market access engagement across multiple therapeutic areas. |
| 9 | Bristol Myers Squibb | bms.com | Senior Director, R&D Operations | Large-scale drug development organization with recurring need for external support, platforms, and strategic partners. |
| 10 | Eli Lilly and Company | lilly.com | Director, Clinical Trial Innovation | Strong buyer for AI, automation, patient engagement, and study optimization solutions. |
| 11 | Amgen | amgen.com | Director, Translational Medicine | Good match for R&D innovation, biomarker strategy, and development-focused vendors. |
| 12 | Takeda | takeda.com | Global Head, Medical Affairs | Global life sciences company with broad medical and development priorities across regions. |
| 13 | IQVIA | iqvia.com | VP, Clinical Operations Services | Major CRO and data services buyer with ongoing demand for technology, analytics, and operational services. |
| 14 | Labcorp Drug Development | labcorp.com | Executive Director, Project Management | Strong buyer for trial support, lab services, and outsourced development capabilities. |
| 15 | ICON plc | iconplc.com | Director, Business Development | High-value CRO target with broad need for service partners, technology providers, and specialist vendors. |
| 16 | Medidata | medidata.com | Product Marketing Director | Digital clinical platform company likely interested in partnerships, buyer conversations, and industry networking. |
| 17 | Thermo Fisher Scientific | thermofisher.com | Global Marketing Director, Life Sciences | Large life sciences supplier with strong presence in lab, clinical, and biopharma ecosystems. |
| 18 | Siemens Healthineers | siemens-healthineers.com | Director, Regulatory & Clinical Affairs | Excellent fit for regulated healthcare innovation, diagnostics, and evidence-generation conversations. |
Top 5 accounts to send first: Pfizer, Roche, Novartis, IQVIA, Thermo Fisher Scientific. These names combine strong brand recognition, global reach, and high relevance to clinical, regulatory, research, and healthcare innovation buying behavior.
5️⃣ Job profiles, industries & event type
Best job profiles to target:
- VP / Director / Head of Clinical Operations
- Director, Clinical Development
- Head of Regulatory Affairs
- Director, Drug Safety / Pharmacovigilance
- Director, Medical Affairs
- Director, R&D Operations
- Clinical Trial Manager
- Global Project Manager
- Head of Data Management
- Biostatistics Director
- Director, Quality Assurance
- Director, Market Access
- Director, Real-World Evidence
- Business Development Director, CRO / CRO Services
- Digital Health Partnerships Lead
- Patient Engagement Lead
- Vendor Management / Outsourcing Manager
- Scientific Affairs Lead
Best industries to use for targeting:
- Pharmaceuticals
- Biotechnology
- Medical Devices
- Hospital & Health Care
- Research
- Information Services
- Information Technology & Services
- Computer Software
- Management Consulting
- Professional Training & Coaching
- Market Research
- Regulatory, compliance, and quality-related organizations
- Contract Research Organizations and clinical service providers
Event type classification: This is a senior B2B conference for life sciences decision makers, with strong buyer intent around outsourcing, digital transformation, trial optimization, regulatory support, safety, and cross-functional collaboration.
6️⃣ Estimated attendance / expected footfall
DIA annual meetings typically attract a substantial professional audience. For business planning and lead targeting, you should expect:
- Total attendance: Several thousand attendees
- Primary buying audience: Senior and mid-level life sciences professionals
- Buyer density: Very high compared with general conferences because most attendees work in regulated healthcare and drug development functions
The key point is not just volume; it is concentration of buying authority. Even when attendees are not final budget owners, they often influence vendor selection, platform adoption, outsourcing decisions, and partner shortlists.
7️⃣ Key focus areas & buyer engagement
Main focus areas likely to dominate conversations:
- Clinical development and trial execution
- Regulatory strategy and global submission readiness
- Drug safety and pharmacovigilance
- Medical affairs and scientific exchange
- Data management, analytics, and AI-driven workflows
- Real-world evidence and market access
- Patient-centric trial design and engagement
- Decentralized and hybrid clinical trials
- Quality, compliance, validation, and inspection readiness
- Outsourcing, vendor selection, and CRO partnerships
- Digital health and life sciences technology adoption
- Global collaboration across regulators, sponsors, and service providers
Buyer engagement angle: This event works best when your message is positioned around high-value life sciences decision makers, not just “attendees.” The strongest lead generation angles are:
- Clinical operations and trial execution buyers
- Regulatory and compliance leaders
- Drug safety and medical affairs teams
- CRO and outsourced development decision makers
- Digital transformation and data leaders in pharma and biotech
If your client sells services or technology into life sciences, this show is one of the best places to identify organizations that are actively investing in trials, regulatory work, medical communications, evidence generation, and commercialization support.
8️⃣ Client product fit note
I can refine the best buyer targets much more accurately if you share your client website. The ideal buyer list changes depending on what the client sells.
Examples:
- If the client sells clinical trial software, prioritize clinical operations, data management, and digital transformation leaders.
- If the client sells regulatory consulting or submission tools, prioritize regulatory affairs, quality, and compliance teams.
- If the client sells pharma services or CRO solutions, prioritize outsourcing heads, project managers, and business development leaders at sponsor companies.
- If the client sells lab equipment or life sciences technology, prioritize R&D, translational medicine, bioanalytics, and procurement-influencing teams.
- If the client sells marketing, data, or healthcare communications, prioritize medical affairs, market access, HEOR, and insights teams.
Once you share the client website, the buyer list can be narrowed to the best-fit accounts and the most relevant decision-maker titles.
9️⃣ Industry suggestions based on your industry list
For this event, the best industry filters from your list are:
- Pharmaceuticals
- Biotechnology
- Medical Devices
- Hospital & Health Care
- Research
- Information Technology & Services
- Computer Software
- Information Services
- Market Research
- Management Consulting
- Professional Training & Coaching
- Health, Wellness & Fitness
- Higher Education
- Public Policy
- Government Relations
Final recommendation
The DIA Global Annual Meeting is a strong event for attendee-list intelligence if your goal is to reach senior professionals in pharma, biotech, clinical research, regulatory affairs, medical affairs, and life sciences technology. It is particularly valuable for B2B companies selling into highly regulated healthcare and drug development environments.
Best buyer groups to collect: pharma sponsors, biotech innovators, CROs, medtech companies, clinical technology providers, regulatory service firms, consulting firms, and digital health vendors.
Quality rating for B2B attendee-list sales: 9/10
The only real caution is that you should segment carefully by function and seniority. The event is broad, but the most valuable prospects are the professionals involved in buying, influencing, or approving clinical, regulatory, data, safety, and outsourcing solutions.
Data sheet
DIA 2026 Global Annual Meeting – Event Attendee & Buyer Profile Analysis
Event date: June 14–18, 2026
Location: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States
Event status: Completed
Research date: June 27, 2026
Event Overview
| Event Name | DIA 2026 Global Annual Meeting |
| Event Date | June 14–18, 2026 |
| Event Status | Completed |
| Venue | Pennsylvania Convention Center |
| City | Philadelphia |
| State / Region | Pennsylvania |
| Country | United States |
| Organizer | Drug Information Association (DIA) |
| Official Event Website | diaglobal.org / annualmeeting.diaglobal.org |
| Event Type | Global annual meeting and conference for life sciences, drug development, regulatory affairs, clinical research, medical affairs, safety, market access, and healthcare innovation. |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; IT & Technology |
| Audience Reach | Global |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. Planning estimate: several thousand participants based on the event’s flagship global positioning and historical market standing. |
| Attendance Data Reliability | Estimated. Current-year public attendance total not confirmed in reviewed official sources. |
| Main Purpose of Event | To connect pharmaceutical, biotechnology, CRO, regulatory, clinical, safety, medical affairs, digital health, and market access stakeholders for knowledge exchange, regulatory dialogue, innovation review, business development, and supplier evaluation. |
About the Event
DIA Global Annual Meeting is one of the best-known cross-functional life sciences conferences for professionals involved in pharmaceutical development, clinical trials, regulatory strategy, pharmacovigilance, medical affairs, market access, and health innovation. The event typically brings together professionals from large pharmaceutical companies, biotechnology firms, clinical research organizations, service providers, regulators, academia, patient-focused organizations, and technology vendors serving drug development workflows.
From a commercial perspective, the event matters because it concentrates high-value decision makers and influencers across the product-development lifecycle rather than a single functional niche. That makes it especially relevant for supplier discovery, partnership outreach, regulatory intelligence, clinical operations networking, technology evaluation, and enterprise account mapping across North America and major global biopharma hubs.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Clinical operations leaders | Pharma, biotech, CROs, academic research centers | Evaluate trial delivery tools, site support, patient recruitment, eClinical platforms, outsourcing partners | High value for CROs, CTMS, EDC, patient engagement, and decentralized trial vendors |
| Regulatory affairs professionals | Pharma, biotech, medical device, consultants, regulators | Influence submission strategy, labeling, policy interpretation, compliance workflows | Strong fit for regulatory software, publishing, document management, advisory, and policy intelligence suppliers |
| Drug safety / pharmacovigilance teams | Pharma, biotech, CROs, safety service providers | Assess safety databases, signal detection, case processing, and risk management partners | High-value buyers for PV technology, automation, AI, and outsourced safety operations |
| Medical affairs and scientific communications leaders | Pharma, biotech, specialty therapeutics companies | Influence KOL engagement, evidence communication, field medical tools, and education programs | Relevant for med comms, MSL enablement, content platforms, and evidence-generation providers |
| R&D and translational medicine leaders | Biopharma, biotech, research institutes | Evaluate platform technologies, development partners, data tools, and biomarker capabilities | Relevant for research software, lab informatics, biomarker analytics, and development services |
| Quality and compliance leaders | Pharma, biotech, CROs, manufacturing support organizations | Select audit, quality management, validation, and inspection-readiness solutions | Strong fit for QMS providers, GxP consultants, training firms, and inspection support services |
| Market access and HEOR teams | Pharma, biotech, consultancies | Influence evidence strategy, pricing support, reimbursement analytics, and payer engagement tools | Relevant for HEOR, RWE, outcomes analytics, and market access advisory providers |
| Procurement and strategic sourcing teams | Large pharma, biotechnology companies, CROs | Own vendor evaluation, RFP management, outsourcing, and budget control | Key audience for supplier onboarding, outsourcing, and enterprise service sales |
| Digital health and data leaders | Biopharma, health tech, platform vendors, innovation teams | Assess AI, real-world data, patient monitoring, and digital enablement solutions | Good fit for software, analytics, interoperability, AI, and patient-tech suppliers |
| Regulators and policy stakeholders | FDA, EMA-related bodies, health authorities, public policy institutions | Shape guidance, standards, and dialogue that affect buying and compliance decisions | Important for thought leadership, policy engagement, and credibility building |
| CRO and service-provider business leaders | CROs, consultancies, specialist service firms | Buy complementary services, partnerships, subcontracting support, and platforms | High partnership and channel value in addition to direct buyer potential |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Philadelphia | Local life sciences professionals, academic medicine, health systems, regional pharma support ecosystem | Medium to High | Host city supports easy access for Mid-Atlantic pharma, biotech, and research stakeholders. |
| Pennsylvania / Mid-Atlantic | Pennsylvania, New Jersey, Delaware, Maryland, Washington D.C. corridor | Very High | Strong concentration of pharmaceutical headquarters, CRO activity, policy institutions, and regulatory affairs talent. |
| Northeast U.S. hubs | Boston/Cambridge, New York metro, New Jersey biopharma corridor | Very High | Major source of biotech, pharma R&D, regulatory, and medical affairs attendees. |
| National U.S. | California, North Carolina, Illinois, Texas, Massachusetts, Maryland, Indiana and other life sciences markets | High | Flagship conference format supports broad U.S. draw across commercial, regulatory, and clinical functions. |
| Europe | United Kingdom, Switzerland, Germany, France, Belgium, Netherlands, Ireland, Nordics | High | DIA’s international brand and regulatory relevance typically attract European participation. |
| Asia-Pacific | Japan, Singapore, South Korea, China, Australia, India | Medium to High | Likely attendance from global pharma, regional biotech, and outsourced development organizations. |
| Other international markets | Canada, Latin America, Middle East and selected emerging biopharma markets | Medium | International draw is credible, but concentration is usually strongest in North America and Europe. |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The meeting is positioned as a global annual gathering for life sciences and regulatory stakeholders and is likely to draw multinational pharmaceutical, biotechnology, and CRO participation. |
| National | Strong secondary reach | The U.S. remains a core attendee base due to domestic pharma concentration, FDA relevance, and the host location. |
| Regional | High Mid-Atlantic pull | Philadelphia and the surrounding Mid-Atlantic corridor support strong regional participation from pharma, CRO, and policy communities. |
4. Sample Buyer Companies and Websites
Prior-year participation evidence may exist in official DIA agendas, speaker programs, sponsor materials, or exhibitor resources for past editions. Not a confirmed attendee list for the current edition. Current-year buyer attendance by company was not publicly confirmed in the reviewed sources.
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| U.S. Food and Drug Administration | Government / regulatory organization | Core policy and regulatory stakeholder for drug development, submissions, safety, and compliance dialogue. | fda.gov | Regulatory Affairs Director, Policy Lead, Safety Lead, Submission Strategy Lead | Confirmed Government / Procurement Organization |
| Pfizer | Pharmaceutical company | Large global buyer of clinical, regulatory, safety, medical affairs, and digital solutions. | pfizer.com | VP Clinical Operations, Director Regulatory Affairs, Procurement Director, Medical Affairs Lead | Prior-Year Participation Evidence |
| Merck & Co. | Pharmaceutical company | Relevant buyer for development operations, pharmacovigilance, market access, and outsourcing categories. | merck.com | Head of Drug Safety, Clinical Program Director, Strategic Sourcing Manager, Quality Director | Prior-Year Participation Evidence |
| Johnson & Johnson Innovative Medicine | Pharmaceutical company | Large enterprise buyer across R&D, evidence generation, safety, and medical affairs functions. | jnj.com | Clinical Operations Director, Medical Affairs Director, Vendor Management Lead, Data Strategy Director | Prior-Year Participation Evidence |
| Novartis | Pharmaceutical company | Relevant for regulatory, digital health, market access, and clinical innovation sales. | novartis.com | Head of Regulatory Affairs, Clinical Innovation Lead, Procurement Manager, HEOR Director | Prior-Year Participation Evidence |
| Roche / Genentech | Pharma / biotech group | High-value buyer for diagnostics-linked development, evidence generation, and advanced trial operations. | roche.com | Clinical Development Director, Safety Systems Lead, Medical Affairs Executive, Global Sourcing Lead | Prior-Year Participation Evidence |
| AstraZeneca | Pharmaceutical company | Relevant for enterprise procurement, clinical technology, and global development service buying. | astrazeneca.com | Director Clinical Operations, VP Regulatory Affairs, Supplier Relationship Manager, Data Science Director | Prior-Year Participation Evidence |
| Bristol Myers Squibb | Pharmaceutical company | Likely buyer segment across oncology development, safety, quality, and medical affairs. | bms.com | Clinical Program Director, Safety Director, Medical Affairs Lead, Strategic Sourcing Director | Prior-Year Participation Evidence |
| Sanofi | Pharmaceutical company | Relevant for market access, regulatory, digital health, and outsourced development services. | sanofi.com | Global Regulatory Lead, Medical Director, Market Access Director, Vendor Management Lead | Prior-Year Participation Evidence |
| Takeda | Pharmaceutical company | Important buyer for clinical outsourcing, rare disease programs, quality, and data-driven development. | takeda.com | Clinical Operations Head, Regulatory Strategy Director, Procurement Manager, Quality Lead | Prior-Year Participation Evidence |
| Amgen | Biotechnology company | Relevant buyer across late-stage development, evidence generation, and safety operations. | amgen.com | Development Director, Pharmacovigilance Director, Medical Affairs Director, Strategic Sourcing Lead | Prior-Year Participation Evidence |
| Biogen | Biotechnology company | Buyer relevance in neuroscience development, regulatory affairs, and patient-focused innovation. | biogen.com | Clinical Development Lead, Regulatory Affairs Director, Patient Engagement Lead, Category Manager | Prior-Year Participation Evidence |
| Regeneron | Biotechnology company | Relevant for clinical, safety, and regulatory software and outsourced service categories. | regeneron.com | Director Clinical Operations, PV Director, Procurement Lead, Program Director | Prior-Year Participation Evidence |
| IQVIA | CRO / analytics / technology company | Important buyer and partner for trial technology, data services, safety, and outsourced delivery ecosystems. | iqvia.com | VP Partnerships, Delivery Director, Clinical Technology Director, Procurement Director | Prior-Year Participation Evidence |
| Parexel | CRO | Buyer and channel partner candidate for clinical operations, regulatory, and patient-focused service delivery. | parexel.com | Delivery Director, Regulatory Consulting Director, Partnerships Lead, Procurement Manager | Prior-Year Participation Evidence |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | VP Clinical Operations | Clinical Development | VP | Owns trial execution priorities and influences major vendor and platform decisions. |
| 2 | Director of Clinical Operations | Clinical Operations | Director | Directly evaluates execution partners, trial technology, and process improvement tools. |
| 3 | Head of Regulatory Affairs | Regulatory Affairs | Director / VP | Key stakeholder for submission strategy, compliance systems, and regulatory intelligence. |
| 4 | Drug Safety Director | Pharmacovigilance / Safety | Director | Influences safety operations, case processing, signal detection, and PV automation purchases. |
| 5 | Medical Affairs Director | Medical Affairs | Director | Drives demand for scientific communications, field tools, and evidence dissemination support. |
| 6 | Strategic Sourcing Manager | Procurement | Manager | Controls vendor shortlists, RFPs, and category evaluation for outsourced services. |
| 7 | Director of Procurement | Procurement | Director | Important for enterprise service contracts, preferred supplier lists, and budget approval. |
| 8 | Quality Director | Quality / Compliance | Director | Buyer for QMS, audit readiness, training, validation, and GxP service support. |
| 9 | Market Access Director | Market Access / HEOR | Director | Relevant for evidence strategy, RWE, HEOR analytics, and payer-facing support. |
| 10 | Program Manager / Clinical Trial Manager | Program Management / Clinical | Manager | Operational influencer with direct visibility into vendor performance and workflow pain points. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Core audience for drug development, submissions, safety, and market access. | Enterprise buyers of clinical, regulatory, safety, and medical affairs solutions |
| 2 | Biotechnology | Strong representation from emerging and established biotechs. | Platform, outsourcing, and regulatory support sales |
| 3 | Medical Devices | Relevant where combined product development, evidence, and regulatory functions overlap. | Regulatory, quality, and post-market support outreach |
| 4 | Hospital & Health Care | Relevant for academic medical centers, trial sites, and health-system research functions. | Clinical site engagement and evidence collaboration |
| 5 | Research | Applies to institutes, translational groups, and scientific organizations involved in development. | Research partnerships and scientific platform sales |
| 6 | Information Technology & Services | Supports life sciences software, analytics, interoperability, and digital transformation vendors. | eClinical, regulatory tech, data, AI, and workflow automation |
| 7 | Computer Software | Useful for targeting specialized software firms selling into life sciences. | Safety systems, QMS, submissions, content, analytics |
| 8 | Management Consulting | Regulatory, quality, market access, and transformation advisers are active in this market. | Advisory partnerships and referral channels |
| 9 | Government Administration | Relevant for health authority and policy stakeholders. | Policy engagement and compliance alignment |
| 10 | Professional Training & Coaching | Relevant for regulated-industry education, compliance training, and capability development. | Training, certification, and upskilling solutions |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Several thousand attendees | Estimated | Flagship global meeting positioning and historical market standing | Attendance figure not publicly confirmed by the organizer. |
| Exhibitor count | Not publicly confirmed in reviewed sources | Unconfirmed | Official website review | Could be available in prospectus or floor plan, but not verified here. |
| Buyer count | Not publicly confirmed | Unconfirmed | No public buyer-only count identified | Audience is mixed across industry, regulators, academia, and solution providers. |
| Speaker count | Large multi-track speaker faculty expected | Estimated | Typical conference structure for DIA annual meetings | Current-year final speaker total not confirmed in reviewed sources. |
| Sponsor count | Not publicly confirmed in reviewed sources | Unconfirmed | Official site review | Sponsor roster may exist in archived event materials. |
| Historical attendance | Large global industry gathering | Historical / prior-year evidence | DIA flagship annual meeting market reputation | Use for planning only, not as a confirmed 2026 headcount. |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Clinical research and trial operations | Faster enrollment, site performance, decentralized support, trial efficiency | Operational pain-point conversations with trial managers and clinical leaders | CRO services, eClinical tools, patient recruitment, remote monitoring, site tech |
| Regulatory affairs | Submission quality, policy tracking, global compliance, document control | Thought leadership on global regulatory change and workflow modernization | Regulatory software, publishing, advisory, intelligence platforms |
| Drug safety | Scalable PV operations, automation, signal detection, case processing quality | Direct outreach to safety heads and PV operations leaders | Safety databases, automation, AI tools, outsourced pharmacovigilance |
| Medical affairs | Scientific exchange, evidence communication, MSL enablement, KOL programs | Engage scientific and medical leaders around evidence storytelling and field execution | Medical communications, MSL platforms, content ops, analytics |
| Quality and compliance | Inspection readiness, CAPA, training, validation, audit workflows | High-value conversations with QA leaders and compliance owners | QMS systems, audit tools, GxP consulting, training services |
| Market access and HEOR | Evidence generation, payer value proof, pricing support | Target HEOR and access leaders with outcomes-focused messaging | RWE analytics, HEOR consulting, market access data services |
| Digital transformation and AI | Workflow automation, data integration, intelligence, risk reduction | Strong meeting-booking opportunity with innovation and data teams | AI platforms, analytics, life sciences software, process automation |
| Partnerships and outsourcing | Flexible specialist capacity, global delivery, expertise access | Business development and procurement-led supplier evaluation conversations | CRO, FSP, consulting, niche scientific and regulatory services |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Audience is highly aligned to regulated life sciences decision making and operational buying. |
| Decision-maker availability | High | Director-, VP-, and function-head-level participation is likely across core departments. |
| Data collection potential | Medium | Strong for networking, agenda mining, sponsor mapping, and LinkedIn/Apollo enrichment; weaker if attendee rosters are private. |
| Apollo targeting potential | Very High | Pharma, biotech, CRO, and regulatory functions are highly targetable by title, department, and company type. |
| Geographic targeting potential | High | Can target U.S. biopharma hubs first, then expand to Europe and APAC clusters. |
| Best outreach approach | High | Use topic-led outreach tied to regulatory change, trial efficiency, safety modernization, and medical affairs outcomes. |
| Overall lead quality | Very High | Particularly strong for enterprise B2B sales into life sciences workflows and outsourced services. |
| Best use case | High | Account-based outreach, event-driven prospecting, sponsor mapping, speaker-org targeting, and pharma/CRO pipeline building. |
| Limitations / risks | Medium | Public attendee-company confirmation may be limited; many visible organizations may be speakers or exhibitors rather than confirmed buyers. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals; Biotechnology; Medical Devices; Hospital & Health Care; Research; Information Technology & Services; Computer Software; Management Consulting; Government Administration | Build a focused life sciences target universe with supporting service and policy stakeholders. |
| Departments | Clinical, Research, Regulatory Affairs, Medical Affairs, Quality, Procurement, Operations, Information Technology, Business Development | Capture both economic buyers and operational influencers. |
| Seniority | Manager; Director; VP; Head; C-Level | Prioritize decision makers while retaining strong functional operators. |
| Job titles | VP Clinical Operations; Director Clinical Operations; Head of Regulatory Affairs; Regulatory Affairs Director; Drug Safety Director; Pharmacovigilance Director; Medical Affairs Director; Director Quality; Strategic Sourcing Manager; Director Procurement; Market Access Director; Program Manager; Clinical Trial Manager | Targets the most event-relevant buying and influence roles. |
| Geography | United States; Pennsylvania; New Jersey; Massachusetts; California; Maryland; North Carolina; Illinois; United Kingdom; Switzerland; Germany; France; Ireland; Belgium; Netherlands; Japan; Singapore | Aligns with the most relevant biopharma clusters for this event. |
| Employee size | 201–500; 501–1,000; 1,001–5,000; 5,001–10,000; 10,001+ | Best for enterprise and growth-stage life sciences buyers with formal budgets. |
| Keywords | clinical development, clinical operations, pharmacovigilance, regulatory affairs, drug safety, medical affairs, market access, quality systems, GxP, submissions, patient engagement, decentralized trials, real world evidence | Improves relevance where title taxonomies vary across companies. |
| Technologies | Use only if relevant to your offer: Veeva, Oracle, Medidata, Salesforce, safety databases, CTMS, QMS, eTMF | Useful for install-base targeting and displacement campaigns. |
| Revenue range | Prefer mid-market to enterprise where available | Helps prioritize accounts with budget and multi-team buying centers. |
| Company type | Public companies; private companies; subsidiaries of major pharma groups; CROs; research institutions; government bodies | Supports direct buyers, channel partners, and policy stakeholders. |
Suggested Apollo Search Logic: ("clinical operations" OR "clinical development" OR "regulatory affairs" OR pharmacovigilance OR "drug safety" OR "medical affairs" OR "market access" OR quality) AND (Director OR VP OR Head OR Manager) AND (Pharmaceuticals OR Biotechnology OR Medical Devices OR Research). For sourcing teams, run a second search using ("strategic sourcing" OR procurement OR "vendor management" OR outsourcing) within Pharmaceuticals, Biotechnology, and CRO-like organizations.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| DIA Global | Official organizer website | Organizer identity, event portfolio, annual meeting branding, life sciences focus | High |
| DIA Annual Meeting | Official event website | Event identity, program positioning, participant profile, current-year event references where published | High |
| Pennsylvania Convention Center | Official venue website | Venue identity and host location verification | High |
| U.S. Food and Drug Administration | Official government website | Regulatory organization relevance to DIA audience profile | High |
| User-supplied event details | Provided brief | City, state, country, venue, start date, end date, and topical scope | Medium to High |
| Verification note | Research constraint | Public current-year attendee totals, named buyer lists, and full sponsor/exhibitor counts were not confirmed in the reviewed official materials available for this report. | Important caution |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to DIA 2026 Global Annual Meeting — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds